Jonah Feldman

The first patient was treated in a study of continuous subcutaneous administration of lenalidomide in multiple myeloma.

The NCCN guidelines now include the Merlin CP-GEP assay as part of shared decision-making for a sentinel lymph node biopsy in patients with melanoma.

Preclinical and early clinical data showed that a proteasome inhibitor could increase BCMA expression after failure of CAR T-cell therapy.

An overview of the FDA’s draft guidance on MRD as a clinical trial end point, with expert insight on what it means for drug development in multiple myeloma.

Circulating tumor DNA showed potential as a dynamic biomarker in assessing response to immune checkpoint inhibitors in melanoma.

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the EXCALIBER-RRMM trial.

Cabozantinib plus temozolomide led to favorable short-term progression-free survival in a single-arm trial of patients with advanced leiomyosarcoma.

FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

A real-world ciltacabtagene autoleucel (cilta-cel) study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.

FDA approves D-VRd, a groundbreaking treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, enhancing survival rates.

The FDA awarded fast track designation to a trispecific antibody targeting BCMA, GPRC5D, and CD3 in multiple myeloma.

The FDA gave breakthrough therapy designation to bezuclastinib plus sunitinib in imatinib-refractory gastrointestinal stromal tumors.

The FDA gave clearance to the IND for a randomized trial of the DNA vaccine iSCIB1+ based on positive single-arm data in combination with dual checkpoint inhibitors.

Higher doses of anti–T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

The FDA released draft guidance on minimal residual disease and complete response as trial end points to accelerate multiple myeloma drug approvals.

Nivolumab after CAR T-cell therapy failure produced responses in only a small percentage of patients with myeloma or non-Hodgkin lymphoma, although responses in myeloma appeared durable.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.

An mRNA neoantigen therapy maintained long-term recurrence-free survival as an adjuvant for melanoma, compared with pembrolizumab alone.

Topline results from the MajesTEC-9 study showed superior progression-free survival and overall survival for teclistamab in patients with 1 to 3 prior lines of treatment for multiple myeloma.

A single-cell atlas of patients with multiple myeloma has identified specific immune signatures that predict patient outcomes and treatment responses beyond traditional cytogenetic risk factors.

A retrospective study of patients treated with an alternate dose schedule of ipilimumab plus nivolumab in advanced melanoma found improvements in both tolerability and efficacy.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.